NeuShen Therapeutics
PrivateLast Round
Series B
Sep 3, 2026
Total Funding Raised
$100M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NeuShen Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in September 2026.
NeuShen Therapeutics is a biotechnology company that develops innovative therapies for neurological and psychiatric disorders using AAV-based gene therapy and small molecule discovery platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuShen Therapeutics Comparables
Compare NeuShen Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SciNeuro Pharmaceuticals | 87% | |
| Sensorium Therapeutics | 83% | |
| Zhongze Therapeutics | 83% |
For institutional investors. Book with your work email.
NeuShen Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 3, 2026 | ||||
| Series A Extension | Jan 28, 2026 | ||||
| Series A | Apr 18, 2025 | ||||
| Pre Seed | Sep 29, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuShen Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shanghai Healthcare Capital | Series A Extension, Series A |
| B Capital Group | Series B |
| ZhenFund | Series B |
| Lapam Capital | Series A Extension, Series A, Pre Seed |
| Shanghai State-owned Capital Investment | Series B |
| Legend Capital | Series B |
| 上海国投先导私募基金管理有限公司 | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
$80M round with participation from B Capital Group and Legend Capital.
- Aug 20, 2026
Monthly visitors grew 111% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 4, 2026
On Sep 7th '26, NeuShen Therapeutics, Inc. closes an oversubscribed Series B exceeding $80M, led by an undisclosed industry investor with participation from B Capital, Legend Capital, Matrix Partners China, ZhenFund, Shanghai State-owned Capital Investment, and Lilly Asia Ventures, to support global clinical development of its CNS pipeline and expansion into additional indications in China and Massachusetts.
For institutional investors. Book with your work email.
NeuShen Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuShen Therapeutics's valuation, stock price, and market status.
Is NeuShen Therapeutics a public or private company?
NeuShen Therapeutics is a private company.
What is the current stock price of NeuShen Therapeutics?
NeuShen Therapeutics is a private company, so its shares have no public market price. Caplight tracks NeuShen Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuShen Therapeutics worth (valuation)?
Valuation information for NeuShen Therapeutics is not publicly available.
Can I buy NeuShen Therapeutics stock?
NeuShen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuShen Therapeutics's last funding round?
NeuShen Therapeutics's most recent funding round was Series B on September 3, 2026.
Who are the main investors in NeuShen Therapeutics?
Key investors in NeuShen Therapeutics include Lapam Capital, Lilly Asia Ventures.
Will NeuShen Therapeutics IPO soon?
No public IPO plans have been announced for NeuShen Therapeutics.
How can I track NeuShen Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NeuShen Therapeutics's shares on secondary markets.